TY - JOUR
T1 - Structural and functional diversity among agonist-bound states of the GLP-1 receptor
AU - Cary, Brian P.
AU - Deganutti, Giuseppe
AU - Zhao, Peishen
AU - Truong, Tin T.
AU - Piper, Sarah J.
AU - Liu, Xinyu
AU - Belousoff, Matthew J.
AU - Danev, Radostin
AU - Sexton, Patrick M.
AU - Wootten, Denise
AU - Gellman, Samuel H.
N1 - Funding Information:
This work was supported by the National Institutes of Health (R01 GM056414, to S.H.G.). B.P.C. was supported in part by a graduate fellowship from the NSF (DGE-1747503) and by a Biotechnology Training Grant from NIGMS (T32 GM008349). R.D. was supported by a Takeda Science Foundation 2019 Medical Research Grant and Japan Science and Technology Agency PRESTO (18069571). P.M.S. and D.W.
Funding Information:
were supported by an ARC Centre Grant (IC200100052). P.M.S. was supported by the National Health and Medical Research Council of Australia (NHMRC) Program Grant (1150083) and Senior Principal Research Fellowship (1154434). D.W. was supported by NHMRC Project Grants (1126857 and 1184726) and a NHMRC Senior Research Fellowship (1155302). This study made use of the National Magnetic Resonance Facility at Madison, which is supported by NIH grants P41GM136463 and P41RR002301; equipment was purchased with funds from the University of Wisconsin-Madison, the NIH (P41GM103399, S10RR02781, S10RR08438, S10RR023438, S10RR025062, S10RR029220) and the NSF (DMB-8415048, OIA-9977486, BIR-9214394). We thank Promega (Madison, WI) for sharing plasmid DNA encoding NLuc.
Funding Information:
S.H.G. is a cofounder of Longevity Biotech, Inc., which is pursuing biomedical applications for α/β-peptides. P.M.S. receives research funding from Laboratoires Servier in the area of GPCR drug discovery. The current study is 100% independent from all academic or commercial collaborations with industry.
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2022/3
Y1 - 2022/3
N2 - Recent advances in G-protein-coupled receptor (GPCR) structural elucidation have strengthened previous hypotheses that multidimensional signal propagation mediated by these receptors depends, in part, on their conformational mobility; however, the relationship between receptor function and static structures is inherently uncertain. Here, we examine the contribution of peptide agonist conformational plasticity to activation of the glucagon-like peptide 1 receptor (GLP-1R), an important clinical target. We use variants of the peptides GLP-1 and exendin-4 (Ex4) to explore the interplay between helical propensity near the agonist N terminus and the ability to bind to and activate the receptor. Cryo-EM analysis of a complex involving an Ex4 analog, the GLP-1R and Gs heterotrimer revealed two receptor conformers with distinct modes of peptide–receptor engagement. Our functional and structural data, along with molecular dynamics (MD) simulations, suggest that receptor conformational dynamics associated with flexibility of the peptide N-terminal activation domain may be a key determinant of agonist efficacy. [Figure not available: see fulltext.]
AB - Recent advances in G-protein-coupled receptor (GPCR) structural elucidation have strengthened previous hypotheses that multidimensional signal propagation mediated by these receptors depends, in part, on their conformational mobility; however, the relationship between receptor function and static structures is inherently uncertain. Here, we examine the contribution of peptide agonist conformational plasticity to activation of the glucagon-like peptide 1 receptor (GLP-1R), an important clinical target. We use variants of the peptides GLP-1 and exendin-4 (Ex4) to explore the interplay between helical propensity near the agonist N terminus and the ability to bind to and activate the receptor. Cryo-EM analysis of a complex involving an Ex4 analog, the GLP-1R and Gs heterotrimer revealed two receptor conformers with distinct modes of peptide–receptor engagement. Our functional and structural data, along with molecular dynamics (MD) simulations, suggest that receptor conformational dynamics associated with flexibility of the peptide N-terminal activation domain may be a key determinant of agonist efficacy. [Figure not available: see fulltext.]
UR - http://www.scopus.com/inward/record.url?scp=85121637586&partnerID=8YFLogxK
U2 - 10.1038/s41589-021-00945-w
DO - 10.1038/s41589-021-00945-w
M3 - Article
C2 - 34937906
AN - SCOPUS:85121637586
SN - 1552-4450
VL - 18
SP - 256
EP - 263
JO - Nature Chemical Biology
JF - Nature Chemical Biology
IS - 3
ER -